[HTML][HTML] Pancreatic safety of incretin-based drugs—FDA and EMA assessment
AG Egan, E Blind, K Dunder, PA de Graeff… - … England Journal of …, 2014 - Mass Medical Soc
AG Egan, E Blind, K Dunder, PA de Graeff, BT Hummer, T Bourcier, C Rosebraugh
New England Journal of Medicine, 2014•Mass Medical SocPancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to
become a physician, build your knowledge, lead a health care organization, and advance your
career with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical
decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to …
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to
become a physician, build your knowledge, lead a health care organization, and advance your
career with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical
decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to …
After evaluating a safety signal regarding pancreatitis and pancreatic cancer in patients using incretin-based drugs, the Food and Drug Administration and the European Medicines Agency conclude that assertions of a causal association are inconsistent with the data.
The New England Journal Of Medicine